Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a

International Journal of Oncology

Volumn 29, Issue 3, 2006, Pages 705-711

  Andersson, Sonia ^a   Hansson, Berit ^a   Norman, Ingrid ^a   Gaberi, Vera ^a   Mints, Miriam ^a   Hjerpe, Anders ^a   Karlsen, Frank ^b   Johansson, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NorChip AS   (Norway)

Author keywords

CIN; E6 E7; Expression; mRNA; Real time PCR; Viral load

Indexed keywords

E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; MESSENGER RNA; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN P16INK4A; REPRESSOR PROTEIN; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; FEMALE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION; VIRUS LOAD;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, VIRAL; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 33749358318     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.3.705     Document Type: Article

References (49)

1. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958-964, 1993.
2. Davidson M, Schnitzer PG, Bulkow LR, Parkinson AJ, Schloss ML, Fitzgerald MA, et al: The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaska Native women. J Infect Dis 169: 792-800, 1994. (Pubitemid 24102112)
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999. (Pubitemid 29406813)
4. Bosch FX and Munoz N: The viral etiology of cervical cancer. Virus Res 89: 183-190, 2002.
5. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354: 20-25, 1999. (Pubitemid 29304297)
6. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Servical Sancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802, 1995.
7. Munoz N: Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19: 1-5, 2000.
8. Zehbe I and Wilander E: Human papillomavirus infection and invasive cervical neoplasia: a study of prevalence and morphology. J Pathol 18: 270-275, 1997. (Pubitemid 27156838)
9. Clifford GM, Smith JS, Aguado T and Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89: 101-105, 2003. (Pubitemid 36897943)
10. Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
11. Soutter WP and Fletcher A: Invasive cancer of the cervix in women with mild dyskaryosis followed up cytologically. BMJ 308: 1421-1423, 1994. (Pubitemid 24159124)
12. Ho GY, Bierman R, Beardsley L, Chang CJ and Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428, 1998. (Pubitemid 28135669)
13. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al: Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 87: 221-227, 2000. (Pubitemid 30434349)
14. Hudson JB, Bedell MA, McCance DJ and Laiminis LA: Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64: 519-526, 1990.
15. Zur Hausen H: Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 186: 131-156, 1994.
16. Sotlar K, Selinka HC, Menton M, Kandolf R and Bultmann B: Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and non-dysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 69: 114-121, 1998. (Pubitemid 28246996)
17. Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, et al: HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 84: 1219-1226, 2001. (Pubitemid 32511340)
18. Kalantari M, Karlsen F, Kristensen G, Holm R, Hagmar B and Johansson B: Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 17: 146-153, 1998. (Pubitemid 28151014)
19. Lazo PA: Papillomavirus integration: prognostic marker in cervical cancer. Am J Obstet Gynecol 176: 1121-1122, 1997. (Pubitemid 27227537)
20. Kalantari M, Blennow E, Hagmar B and Johansson B: Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas. Diagn Mol Pathol 10: 46-54, 2001.
21. Dong G, Broker TR and Chow LT: Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements. J Virol 68: 1115-1127, 1994.
22. Tan SH, Leong LE, Walker PA and Bernard HU: The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J Virol 68: 6411-6420, 1994.
23. Romanczuk H and Howley PM: Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA 89: 3159-3163, 1992.
24. Jeon S and Lambert PF: Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 92: 1654-1658, 1995.
25. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR, et al: The full-length E6 protein of human papillomavirus type 16 has transforming and transactivating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol 65: 4860-4866, 1991.
26. McNicol P, Guijon F, Wayne S, Hidajat R and Paraskevas M: Expression of human papillomavirus type 16 E6-E7 open reading frame varies quantitatively in biopsy tissue from different grades of cervical intraepithelial neoplasia. J Clin Microbiol 33: 1169-1173, 1995.
27. Bechtold V, Beard P and Raj K: Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J Virol 77: 2021-2028, 2003.
28. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J and Louis DN: Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 79: 1137-1143, 1999.
29. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al: Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92: 276-284, 2001.
30. Sano T, Masuda N, Oyama T and Nakajima T: Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int 52: 375-383, 2002.
31. Linder J and Zahniser D: ThinPrep Papanicolaou testing to reduce false-negative cervical cytology. Arch Pathol Lab Med 122: 139-144, 1998.
32. Vogelstein B and Gillespie D: Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci USA 76: 615-619, 1979.
33. Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, Skare GB, et al: Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 114: 973-976, 2005.
34. Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U and Johansson B: Type distribution, viral load and integration status of high-risk human papillomaviruses in prestages of cervical cancer (CIN). Br J Cancer 95: 2195-2200, 2005.
35. Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
36. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, et al: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325: 572-579, 2002.
37. Beskow AH and Gyllensten UB: Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int J Cancer 101: 526-531, 2002.
38. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, et al: Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 106: 396-403, 2003.
39. Kalantari M, Calleja-Macias IE, Tewari D, Hagmar B, Lie K, Barrera-Saldana HA, et al: Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 78: 12762-12772, 2004.
40. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
41. Vousden K: Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 7: 872-879, 1993.
42. Peitsaro P, Johansson B and Syrjanen S: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40: 886-891, 2002.
43. Dowhanick JJ, McBride AA and Howley PM: Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 69: 7791-7799, 1995.
44. Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F and Hagmar B: Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer 90: 1407-1413, 2004.
45. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, et al: Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358: 1782-1783, 2001.
46. Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P and Gupta P: Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 27: 365-370, 2002. (Pubitemid 35424172)
47. Khleif SN and Frederickson H: The role of vaccines in cancer prevention. Cancer Treat Res 106: 283-306, 2001.
48. Zur Hausen H: Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1288: F55-F78, 1996. (Pubitemid 26335492)
49. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, et al: Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355: 2194-2198, 2000. (Pubitemid 30394326)